Mipomersen and lomitapide: Two new drugs for the treatment of homozygous familial hypercholesterolemia

Atherosclerosis Supplements

Volumn 18, Issue , 2015, Pages 28-34

  Gouni Berthold, Ioanna ^a   Berthold, Heiner K ^b  

^a UNIVERSITY OF COLOGNE   (Germany)

^b EVANGELISCHES KRANKENHAUS   (Germany)

Author keywords

Apolipoprotein B synthesis inhibitor; Familial hypercholesterolemia; Homozygous form; Microsomal transfer protein (MTP) inhibitor

Indexed keywords

LOMITAPIDE; MIPOMERSEN; APOB PROTEIN, HUMAN; APOLIPOPROTEIN B100; BENZIMIDAZOLE DERIVATIVE; BIOLOGICAL MARKER; CARRIER PROTEIN; HYPOCHOLESTEROLEMIC AGENT; LDLR PROTEIN, HUMAN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; LOW DENSITY LIPOPROTEIN RECEPTOR; MICROSOMAL TRIGLYCERIDE TRANSFER PROTEIN; OLIGONUCLEOTIDE;

ABDOMINAL PAIN; ARTICLE; DIARRHEA; DRUG EFFICACY; DRUG SAFETY; DYSPEPSIA; ERYTHEMA; FAMILIAL HYPERCHOLESTEROLEMIA; HEMATOMA; HOMOZYGOTE; HUMAN; NAUSEA; PAIN; PRIORITY JOURNAL; SKIN DISCOLORATION; VOMITING; ANIMAL; ANTAGONISTS AND INHIBITORS; BIOSYNTHESIS; BLOOD; GENETIC PREDISPOSITION; GENETICS; HYPERLIPOPROTEINEMIA TYPE II; METABOLISM; MUTATION; PHENOTYPE; TREATMENT OUTCOME;

ANIMALS; ANTICHOLESTEREMIC AGENTS; APOLIPOPROTEIN B-100; BENZIMIDAZOLES; BIOMARKERS; CARRIER PROTEINS; CHOLESTEROL, LDL; GENETIC PREDISPOSITION TO DISEASE; HOMOZYGOTE; HUMANS; HYPERLIPOPROTEINEMIA TYPE II; MUTATION; OLIGONUCLEOTIDES; PHENOTYPE; RECEPTORS, LDL; TREATMENT OUTCOME;

EID: 84928901740     PISSN: 15675688     EISSN: 18785050     Source Type: Journal    
DOI: 10.1016/j.atherosclerosissup.2015.02.005     Document Type: Article

References (26)

1. Raal F.J., Santos R.D. Homozygous familial hypercholesterolemia: current perspectives on diagnosis and treatment. Atherosclerosis 2012, 223:262-268.
2. Pang J., Chan D.C., Watts G.F. Critical review of non-statin treatments for dyslipoproteinemia. Expert Rev Cardiovasc Ther 2014, 12:359-371.
3. Davidson M.H., Ballantyne C.M., Jacobson T.A., Bittner V.A., Braun L.T., Brown A.S., et al. Clinical utility of inflammatory markers and advanced lipoprotein testing: advice from an expert panel of lipid specialists. J Clin Lipidol 2011, 5:338-367.
4. Nordestgaard B.G., Chapman M.J., Humphries S.E., Ginsberg H.N., Masana L., Descamps O.S., et al. Familial hypercholesterolaemia is underdiagnosed and undertreated in the general population: guidance for clinicians to prevent coronary heart disease: Consensus Statement of the European Atherosclerosis Society. Eur Heart J 2013, 34:3478-3490.
5. Kastelein J.J., Wedel M.K., Baker B.F., Su J., Bradley J.D., Yu R.Z., et al. Potent reduction of apolipoprotein B and low-density lipoprotein cholesterol by short-term administration of an antisense inhibitor of apolipoprotein B. Circulation 2006, 114:1729-1735.
6. Yu R.Z., Kim T.W., Hong A., Watanabe T.A., Gaus H.J., Geary R.S. Cross-species pharmacokinetic comparison from mouse to man of a second-generation antisense oligonucleotide, ISIS 301012, targeting human apolipoprotein B-100. Drug Metab Dispos 2007, 35:460-468.
7. Dixon D.L., Sisson E.M., Butler M., Higbea A., Muoio B., Turner B. Lomitapide and mipomersen: novel lipid-lowering agents for the management of familial hypercholesterolemia. J Cardiovasc Nurs 2013, 29:E7-E12.
8. Akdim F., Tribble D.L., Flaim J.D., et al. Efficacy of apolipoprotein B synthesis inhibition in subjects with mild-to-moderate hyperlipidaemia. Eur Heart J 2011, 32:2650-2659.
9. Akdim F., Stroes E.S., Sijbrands E.J., Tribble D.L., Trip M.D., Jukema J.W., et al. Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy. J Am Coll Cardiol 2010, 55:1611-1618.
10. Raal F.J., Santos R.D., Blom D.J., Marais M.J., Charng M.J., Cromwell W.C., et al. Mipomersen, an apolipoprotein B synthesis inhibitor, for lowering of LDL cholesterol concentrations in patients with homozygous familial hypercholesterolaemia: a randomised, double-blind, placebo-controlled trial. Lancet 2010, 375:998-1006.
11. Akdim F., Visser M.E., Tribble D.L., Baker B.F., Stroes E.S., Yu R., et al. Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia. Am J Cardiol 2010, 105:1413-1419.
12. Stein E.A., Dufour R., Gagne C., Gaudet D., East C., Donovan J.M., et al. Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease. Circulation 2012, 126:2283-2292.
13. McGowan M.P., Tardif J.C., Ceska R., Burgess L.J., Soran H., Gouni-Berthold I., et al. Randomized, placebo-controlled trial of mipomersen in patients with severe hypercholesterolemia receiving maximally tolerated lipid-lowering therapy. PLoS One 2012, 7:e49006.
14. Thomas G.S., Cromwell W.C., Ali S., Chin W., Flaim J.D., Davidson M. Mipomersen, an apolipoprotein B synthesis inhibitor, reduces atherogenic lipoproteins in patients with severe hypercholesterolemia at high cardiovascular risk: a randomized, double-blind, placebo-controlled trial. J Am Coll Cardiol 2013, 62:2178-2184.
15. Visser M.E., Wagener G., Baker B.F., Geary R.S., Donovan J.M., Beuers U.H., et al. Mipomersen, an apolipoprotein B synthesis inhibitor, lowers low-density lipoprotein cholesterol in high-risk statin-intolerant patients: a randomized, double-blind, placebo-controlled trial. Eur Heart J 2012, 33:1142-1149.
16. Santos R.D., Duell P.B., East C., Guyton J.R., Moriarty P.M., Chin W., et al. Long-term efficacy and safety of mipomersen in patients with familial hypercholesterolaemia: 2-year interim results of an open-label extension. Eur Heart J 2013.
17. Sjouke B., Balak D.M., Beuers U., Ratziu V., Stroes E.S. Is mipomersen ready for clinical implementation? A transatlantic dilemma. Curr Opin Lipidol 2013, 24:301-306.
18. Flaim J.D., Grundy J.S., Baker B.F., McGowan M.P., Kastelein J.J. Changes in mipomersen dosing regimen provide similar exposure with improved tolerability in randomized placebo-controlled study of healthy volunteers. J Am Heart Assoc 2014, 3:e000560.
19. Milani R.V., Lavie C.J. Lipid control in the modern era: an orphan's tale of rags to riches. J Am Coll Cardiol 2013, 62:2185-2187.
20. Watts G.F., Gidding S., Wierzbicki A.S., Toth P.P., Alonso R., Brown W.V., et al. Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation. Int J Cardiol 2014, 171:309-325.
21. Wong E., Goldberg T. Mipomersen (kynamro): a novel antisense oligonucleotide inhibitor for the management of homozygous familial hypercholesterolemia. P T 2014, 39:119-122.
22. Perry C.M. Lomitapide: a review of its use in adults with homozygous familial hypercholesterolemia. Am J Cardiovasc Drugs 2013, 13:285-296.
23. Cuchel M., Bloedon L.T., Szapary P.O., Kolansky D.M., Wolfe M.L., Sarkis A., et al. Inhibition of microsomal triglyceride transfer protein in familial hypercholesterolemia. N Engl J Med 2007, 356:148-156.
24. Cuchel M., Meagher E.A., du Toit T.H., Blom D.J., Marais A.D., Hegele R.A., et al. Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study. Lancet 2013, 381:40-46.
25. Cuchel M., Rader D.J. Microsomal transfer protein inhibition in humans. Curr Opin Lipidol 2013, 24:246-250.
26. Rader D.J., Kastelein J.J. Lomitapide and mipomersen: two first-in-class drugs for reducing low-density lipoprotein cholesterol in patients with homozygous familial hypercholesterolemia. Circulation 2014, 129:1022-1032.